Ann: Kazia commences recruitment to GBM AGILE, page-5

GBM AGILE pivotal study (NCT03970447) has commenced recruitment to the paxalisib arm.

After seeing yesterday's announcement that Duke University Medical Center was accepted as a new GBM AGILE site and now recruiting, and a week ago Mayo Cancer Care in Jacksonville FL also accepted and now recruiting, it was only a matter of time before GCAR would announce the commencement of the paxalisib arm in the study.

IMO the clinicians now have much more than hope.

https://twitter.com/gcaresearch?lang=en

GBM AGILE will not have any difficulty in recruiting patients after announcing :-
"Kazia's paxalisib and Kintara's VAL-083 are entering the GBM AGILE trial, which initially opened in July 2019 and has screened over 370 patients to date."

Regards.